ArticleInternational journal of hematology2026

Measurable residual disease after venetoclax treatment for relapsed or refractory chronic lymphocytic leukemia in Japan.

Hirotaka Matsui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.